{"id":"im-haloperidol-plus-lorazepam","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Extrapyramidal symptoms (dystonia, akathisia, parkinsonism)"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Respiratory depression (with lorazepam)"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1200986","moleculeType":"Small molecule","molecularWeight":"530.12"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Haloperidol is a typical antipsychotic that antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, effectively reducing hallucinations and delusions. Lorazepam is a benzodiazepine that potentiates GABA-A receptor activity, producing rapid sedation and anxiolytic effects. This combination is used for acute agitation or psychotic episodes requiring rapid behavioral control.","oneSentence":"IM haloperidol blocks dopamine receptors to reduce psychotic symptoms, while lorazepam enhances GABA signaling to provide sedation and anxiolysis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:33.474Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute agitation or psychotic symptoms requiring rapid parenteral intervention"},{"name":"Acute exacerbation of schizophrenia or bipolar disorder"}]},"trialDetails":[{"nctId":"NCT00457366","phase":"PHASE4","title":"A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2006-05","conditions":"Agitation","enrollment":72},{"nctId":"NCT00786318","phase":"PHASE4","title":"Ziprasidone vs Standard Therapy for Agitated Patients in the ED","status":"WITHDRAWN","sponsor":"George Washington University","startDate":"2008-09","conditions":"Psychosis, Agitation, Delirium","enrollment":""},{"nctId":"NCT00797277","phase":"PHASE3","title":"Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-07","conditions":"Schizophrenia, Schizoaffective Disorder, Agitation","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["haldol and ativan"],"phase":"phase_3","status":"active","brandName":"IM haloperidol plus lorazepam","genericName":"IM haloperidol plus lorazepam","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Haloperidol is a serotonin 2a (5-HT2a) receptor antagonist, classified as an antagonist and a small molecule. It is used to treat conditions such as psychosis, agitation, delirium, schizophrenia, and schizoaffective disorder, often in combination with other medications.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}